New York, New York
Jonathan is a Principal at BDC Advisors. He offers his clients sixteen years of experience in the health care industry as a researcher, lecturer, strategic consultant and business development leader. Jonathan worked in a senior executive role with an industry leading for-profit research and consulting firm, and as a market development leader with one of the nation’s largest for-profit biopharmaceutical firms. Specific areas of specialization include:
• Managing Benefit Costs of Hospital Employees
• Hospital and Physician Clinical Integration
• Business Development Strategies and Processes
• Nursing Enterprise Solutions and Outcomes
• Physician Strategy
• Board Management
• Capacity Management
• Oncology and Cardiac Program Optimization
• Hospital Marketing Strategies
Prior to joining BDC Advisors, Jonathan served as a Managing Director of the Advisory Board Company in Washington, D.C., a publicly traded for-profit research, analytics and consulting firm serving more than 3,000 hospitals, health systems and physician practices. During his tenure, Jonathan participated in the development and launch of an analytics-based product designed to support hospitals in managing the cost of employee health benefits. He also served as one of the firm’s National Spokesmen, delivering a wide range of proven best practices to executive and board audiences across the country. As such, Jonathan was deeply immersed across the firm’s fourteen research programs and served as a trusted advisor to more than 30 of the nation’s leading hospitals and health systems.
Jonathan also supported the launch of the firm’s Nursing Executive Center, a membership program designed to arm nurse executives with proven best practices to improve the efficiency, clinical expertise and leadership capabilities of hospital nursing enterprises.
Prior to joining the Advisory Board Company, Jonathan served as Marketing Research Lead at Amgen, one of the nation’s largest biotechnology firms. He supported the branding, marketing and launch of Aranesp, a long lasting version of the firm’s blockbuster biologic agent Epogen. Aranesp achieved sales of $1 billion within six months of launch.
Jonathan holds dual degrees from Georgetown University where he graduated summa cum laude.